SCHEMBL237255

SCHEMBL237255

Nc1c(F)c(F)c(N2CCCCC2)c(F)c1F

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.57
CA1 P00915 2/20 0.57
CA2 P00918 2/20 0.57
CA7 P43166 2/20 0.57
CA13 Q8N1Q1 2/20 0.57
CA9 Q16790 1/20 0.57
ALDH1A1 P00352 7/20 0.41
LMNA P02545 2/20 0.41
GAA P10253 6/20 0.37
HTT P42858 3/20 0.37
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
HSD17B10 Q99714 2/20 0.35
POLB P06746 2/20 0.35
MAPT P10636 2/20 0.35
ALOX15 P16050 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
USP2 O75604 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5716127 0.85 CA12 (0.59) CA12CA1CA2CA7CA13
SCHEMBL5716130 0.82 ALDH1A1 (0.56) CA12CA1CA2CA7CA13
Hydrochloric Acid SCHEMBL7605265 0.79 ALDH1A1 (0.61) CA12CA1CA2CA7CA13
SCHEMBL5715977 0.76 ALDH1A1 (0.56) CA12CA1CA2CA7CA13
SCHEMBL31034606 0.73 CA12 (0.48) CA12CA1CA2CA7CA13
SCHEMBL5716136 0.73 CA12 (0.48) CA12CA1CA2CA7CA13
SCHEMBL240017 0.73 CA12 (0.44) CA12CA1CA2CA7CA13
SCHEMBL17091727 0.73 CA1 (1.00) CA12CA1CA2CA7CA13
SCHEMBL17091719 0.73 CA1 (1.00) CA12CA1CA2CA7CA13
SCHEMBL6581764 0.71 CA12 (0.47) CA12CA1CA2CA7CA13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 US disclosed
EP-3438106-A1 ANTI-VIRAL COMPOUNDS AbbVie Ireland Unlimited Company (IE) 2019-02-06 EP disclosed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 US disclosed
US-10039754-B2 Anti-viral compounds ABBVIE INC. (US) 2018-08-07 US disclosed
US-10028937-B2 Anti-viral compounds ABBVIE INC. (US) 2018-07-24 US disclosed
US-20170157104-A1 Anti-Viral Compounds ABBVIE INC. (US) 2017-06-08 US disclosed
US-20170157105-A1 Anti-Viral Compounds ABBVIE INC. (US) 2017-06-08 US disclosed
EP-2678334-B1 ANTI-VIRAL COMPOUNDS ABBVIE BAHAMAS LTD (BS) 2017-03-22 EP disclosed
US-9586978-B2 Anti-viral compounds ABBVIE INC. (US) 2017-03-07 US disclosed
EP-2692346-B1 An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative ABBVIE BAHAMAS LTD (BS) 2015-12-02 EP disclosed
EP-2692346-A1 An antiviral 1-phenyl-2,5-dibenzimidazol-5-yl-pyrrolidine derivative Abbvie Inc. (US) 2014-02-05 EP disclosed
EP-2692726-A1 Anti-viral compounds Abbvie Inc. (US) 2014-02-05 EP disclosed
EP-2678334-A1 ANTI-VIRAL COMPOUNDS Abbvie Inc. (US) 2014-01-01 EP disclosed
EP-2627651-A1 ANTI-VIRAL COMPOUNDS Abbvie Inc. (US) 2013-08-21 EP disclosed
US-20120220562-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-08-30 US disclosed
WO-2012116257-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. (US) 2012-08-30 WO disclosed
WO-2012051361-A1 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-04-19 WO disclosed
US-20120004196-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2012-01-05 US disclosed
US-20110207699-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-08-25 US disclosed
US-20110092415-A1 Anti-Viral Compounds Abbott Labaoratories (US) 2011-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028937-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS CA12 4401/4885CA1 4852/4885CA2 4674/4885
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS CA12 4401/4885CA1 4852/4885CA2 4674/4885
US-20120220562-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS CA12 4401/4885CA1 4852/4885CA2 4674/4885
US-20170157105-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS CA12 4401/4885CA1 4852/4885CA2 4674/4885
US-20110092415-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS CA12 4401/4885CA1 4852/4885CA2 4674/4885
US-20170157104-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS CA12 4401/4885CA1 4852/4885CA2 4674/4885
US-20110207699-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS CA12 4401/4885CA1 4852/4885CA2 4674/4885
US-20190015402-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS CA12 4401/4885CA1 4852/4885CA2 4674/4885
US-20120004196-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS CA12 4401/4885CA1 4852/4885CA2 4674/4885
US-10039754-B2 Anti-viral compounds HAVCR2, EIF2AK2, MAVS CA12 4401/4885CA1 4852/4885CA2 4674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.